B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has reiterated its Buy rating on Altimmune (NASDAQ:ALT) and maintained a $20 price target, as stated by analyst Mayank Mamtani.
August 12, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has reiterated its Buy rating on Altimmune (NASDAQ:ALT) and maintained a $20 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $20 price target by B. Riley Securities suggests strong confidence in Altimmune's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100